by kapu@raikee.fi | Oct 13, 2023 | News
Desentum today announces the dosing of first subjects in a clinical study evaluating safety and tolerability of its investigational birch pollen allergy vaccine DM-101PX. The study, which is conducted in Canada, also assesses the effect of DM-101PX on allergic...
by kapu@raikee.fi | Sep 14, 2023 | News
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a clinical study on DM-101PX, an investigational preparation intended for immunotherapeutic treatment of birch pollen allergy. The planned study will test three...
by aisla@raikee.fi | Jan 21, 2022 | News
Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros in a funding round arranged by Springvest Oyj. Desentum intends to...
by aisla@raikee.fi | Oct 25, 2021 | News
Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a...
by aisla@raikee.fi | May 11, 2021 | News
Dosing has been completed for all study subjects in Desentum’s First-in-Human clinical study of DM-101, a novel allergy vaccine intended for treating birch pollen allergy. Last follow-up visits will be completed during Q2/2021 and study results are expected in...
by aisla@raikee.fi | Nov 30, 2020 | News
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt. In early 2020, Desentum initiated a clinical study to evaluate the safety and tolerability of DM-101, a hypoallergen designed for treating birch pollen...
